Picture of Cansino Biologics logo

6185 Cansino Biologics Income Statement

0.000.00%
hk flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapSucker Stock

Annual income statement for Cansino Biologics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue1.13018.54,3001,031
Cost of Revenue
Gross Profit4.743,003-187
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses1402004192,3882,400
Operating Profit-139-200-4011,912-1,369
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-138-157-3971,937-1,184
Provision for Income Taxes
Net Income After Taxes-138-157-3971,907-965
Minority Interest
Net Income Before Extraordinary Items
Net Income-138-157-3971,914-909
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-138-157-3971,914-909
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.797-0.698-1.727.73-3.68
Dividends per Share